Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.
Brigitte MichelsenUlf LindströmCatalin CodreanuAdrian CiureaJakub ZavadaAnne Gitte LoftManuel Pombo-SuarezFatos OnenTore K KvienZiga RotarMaria Jose SantosFlorenzo IannoneAnna-Mari HokkanenBjorn GudbjornssonJohan AsklingRuxandra IonescuMichael J NissenKarel PavelkaCarlos Sanchez-PiedraServet AkarJoseph SextonMatija TomsicHelena SantosMarco SebastianiJenny ÖsterlundArni Jon GeirssonGary MacfarlaneIrene van der Horst-BruinsmaStylianos GeorgiadisCecilie Heegaard BraheLykke Midtbøll ØrnbjergMerete Lund HetlandMikkel ØstergaardPublished in: RMD open (2021)
In this study of 1860 patients from 13 European countries, we present the first comprehensive real-life data on effectiveness of secukinumab in patients with axSpA. Overall, secukinumab retention rates after 6 and 12 months of treatment were high. Secukinumab effectiveness was consistently better for bionaïve patients, independent of time since diagnosis and differed across the European countries.
Keyphrases
- ankylosing spondylitis
- systematic review
- randomized controlled trial
- end stage renal disease
- healthcare
- ejection fraction
- chronic kidney disease
- newly diagnosed
- disease activity
- rheumatoid arthritis
- big data
- palliative care
- systemic lupus erythematosus
- combination therapy
- machine learning
- peritoneal dialysis
- clinical practice
- artificial intelligence
- quality improvement
- data analysis
- adverse drug
- smoking cessation